AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company is working to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (“RCC”). The Company has sublicensed tivozanib (FOTIVDA®) for oncological indications in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company also has other product candidates in pre-clinical or clinical development for oncology, age-related macular degeneration and cancer cachexia.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO -3 study of
TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Kyowa Kirin Co., Ltd. , ( Kyowa Kirin , TYO: 4151) and AVEO Oncology (NASDAQ: AVEO ) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that Mike Ferraresso , Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m.